Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.

Show simple item record Garcia-Recio, M. Martinez-Serra, J. Mestre, F. Bento, L. Gines, J. Ramos, R. Daumal, J. López, P. Sampol, A. Gutierrez, A. 2019-09-24T06:45:05Z 2019-09-24T06:45:05Z
dc.description.abstract Abstract: Hodgkin lymphoma (HL) represents ~11% of all lymphoma cases. This disease occurs in young adults, but also affects people over 55 years of age. Despite the fact that >80% of all newly diagnosed patients under 60 will achieve a sustained complete response (CR), 5%-10% of HL patients are refractory to initial treatment and 10%-30% of patients will eventually relapse after an initial CR. The treatment recommendation for primary refractory or relapsed HL patients is salvage therapy followed by high-dose chemotherapy and autologous stem cell transplantation. Following this approach, a significant part will still relapse at any moment. Thus, further research and new drugs or combinations are required. Overexpression of COX-2 has been associated with poor prognosis in relapse/refractory HL patients, so it could be a potential therapeutic target in HL. For this purpose, several drugs may have a role: specific COX-2 inhibitors such as celecoxib or other anti-inflammatory drugs such as lenalidomide may further inhibit lipopolysaccharide-mediated induction of COX-2. Moreover, lenalidomide and COX-2 inhibitors (celecoxib) have been tested in solid tumors with encouraging results. We present a case of a young female diagnosed with a heavily pretreated HL nodular sclerosis subtype who, after failing six treatment lines, only achieved clinical and radiological CR after six cycles of lenalidomide/celecoxib that resulted in an event-free survival of 22 months. We explain the rationale of using this chemotherapy regimen and our patient follow-up.
dc.format application/pdf
dc.relation.ispartof Oncotargets And Therapy, 2018, vol. 11, p. 6599-6603
dc.rights , 2018
dc.subject.classification 616 - Patologia. Medicina clínica. Oncologia
dc.subject.other 616 - Pathology. Clinical medicine
dc.title Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma.
dc.type info:eu-repo/semantics/article 2019-09-24T06:45:05Z
dc.rights.accessRights info:eu-repo/semantics/openAccess

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Repository

Advanced Search


My Account